a Sharett Institute of Oncology , Hadassah-Hebrew University Medical Center , Jerusalem , Israel.
Cancer Biol Ther. 2019;20(8):1057-1067. doi: 10.1080/15384047.2019.1598759. Epub 2019 Apr 16.
Tumor-specific, circulating cell-free DNA in liquid biopsies is a promising source of biomarkers for minimally invasive serial monitoring of treatment responses in cancer management. We will review the current understanding of the origin of circulating cell-free DNA and different forms of DNA release (including various types of cell death and active secretion processes) and clearance routes. The dynamics of extracellular DNA in blood during therapy and the role of circulating DNA in pathophysiological processes (tumor-associated inflammation, NETosis, and pre-metastatic niche development) provide insights into the mechanisms that contribute to tumor development and metastases formation. Better knowledge of circulating tumor-specific cell-free DNA could facilitate the development of new therapeutic and diagnostic options for cancer management.
液体活检中肿瘤特异性循环游离 DNA 是一种很有前途的生物标志物来源，可用于微创连续监测癌症治疗反应。我们将回顾目前对循环游离 DNA 的来源以及不同形式的 DNA 释放（包括各种类型的细胞死亡和主动分泌过程）和清除途径的理解。治疗过程中外周血中细胞外 DNA 的动力学以及循环 DNA 在病理生理过程（肿瘤相关炎症、NETosis 和前转移龛形成）中的作用，为肿瘤发展和转移形成的机制提供了新的见解。更好地了解肿瘤特异性循环游离 DNA 有助于开发癌症管理的新治疗和诊断选择。
